Halda Therapeutics
Craig Crews has a significant work experience in the field of biology, chemistry, and pharmacology. Craig has founded multiple companies including Siduma Therapeutics in 2021, Halda Therapeutics in 2019, and Arvinas in 2013. Additionally, they have held various roles at Yale University, starting in 1995, where they served as the John C. Malone Professor of Mol., Cellular, and Developmental Biology; Chemistry; Pharmacology. Craig Crews has also been involved in the establishment of the Yale Center for Molecular Discovery in 2003 and Proteolix, where they served as a Co-Founder until 2009.
Craig Crews has a strong educational background in the field of biochemistry and chemical biology. Craig began their academic journey in 1982 at the University of Virginia, where they pursued a Bachelor's degree in Chemistry. After completing their undergraduate studies in 1986, Craig continued their education at the University of Tübingen as a DAAD Fellow, focusing on Microbiology from 1986 to 1987. Craig then returned to Harvard University, where they earned a Doctor of Philosophy (Ph.D.) degree in Biochemistry from 1987 to 1992. Craig further advanced their studies at Harvard University, serving as a Cancer Research Institute Fellow and specializing in Chemical Biology from 1992 to 1995.
Halda Therapeutics
1 followers
Halda is inventing novel precision medicines for oncology. Specifically, we are developing RIPTAC™ therapeutics, a new drug modality for the treatment of cancer. Founded by world renowned Yale scientist, Professor Craig Crews, Halda invented RIPTAC therapeutics as an innovative cancer treatment approach that does not rely on traditional oncogenic disease drivers to target cancer. This powerful technology is designed to overcome the known bypass mechanisms of drug resistance, a common limitation of today’s precision cancer medicines. Using a novel ‘hold and kill’ mechanism, RIPTAC therapeutics target cancer cells selectively by bringing two proteins together in a tightly regulated manner, causing the loss of an essential function for cell survival and subsequent cancer cell death. We have built a pipeline of RIPTAC therapeutics for major cancer types, uniquely addressing the unmet needs of drug resistant cancer patients, and we will continue to invent new medicines using our proprietary platform technology. We are a bold company where collaboration, passion, and creativity thrive, all of which allows us to push the boundaries of drug discovery to identify better solutions. Halda is proud to be a New Haven, CT based biotech, located with headquarters and state-of-the-art labs in Science Park.